Mr. Bruce Clark reports

NIRVANA ANNOUNCES EXTENSION OF WARRANTS

Nirvana Life Sciences Inc. intends to amend the terms of a total of 370,000 share purchase warrants, having a current exercise price of 25 cents per share. The warrants were issued by the company on or about May 25, 2022, and May 25, 2023, with each warrant exercisable to acquire one Class A common share in the capital of the company for a period expiring on May 15, 2026. The expiry date of the warrants will be extended to May 15, 2027. However, if, at any time after the warrant repricing becomes effective, the closing price of the shares, as quoted by the Canadian Securities Exchange, is equal to or greater than 25 cents per share for 10 consecutive trading days, the expiration date of the warrants will automatically be accelerated to the date that is 30 calendar days after the date of such 10-consecutive-trading-day period. Under the policies of the CSE, the proposed warrant repricing is subject to the unanimous consent of the registered holders of the outstanding warrants. If the warrant repricing is approved by holders of the warrants, it is expected that replacement warrant certificates will not be issued and that notice of the amendment will be sent to holders of the warrants. Eight per cent of the warrants are held by insiders of the company.

About Nirvana Life Sciences Inc.

Nirvana is an innovator in the emerging non-addictive addiction treatment space. At Nirvana, it believes that traditional medicines can play a leading role in reducing the impacts of the opioid crisis and build healthier communities.

We seek Safe Harbor.